Peter Thilo Hasler
EUR 149.00 For Business Accounts Only

An Innovative Drug Delivery Platform

We are initiating research coverage of Rapid Dose Therapeutics with a Buy recommendation and a CAD 1.80 price target. Our target price is based on a discounted cash flow entity model.

Founded in 2017, Rapid Dose Therapeutics Corp. (RDT) is a Canadian life science company that provides an innovative, proprietary drug delivery platform. The company has developed an IP protected non-invasive, fast-dissolving and oral dispersible film product infused with micronized active ingredients such as pharmaceuticals, nutraceuticals, or cannabis. While the strip is dissolved in the mouth, the active ingredients are transferred across the mucosal layers or sublingually into the blood stream. With the pharmaceutical, nutraceutical, and the cannabis market, RDT has formed three main business divisions so far, with more to follow in the next years, according to the company.

Sphene Capital GmbH
Sphene Capital GmbH

Founded in 2010, Sphene Capital is a German based pure-play research house offering state-of-the-art research and evaluation services to European small- and mid-caps by avoiding typical conflict of interests of traditional investment banks.

As a general rule, analysts of Sphene Capital strive to understand companies better than any other analyst or investor before publishing their initiation reports. Therefore, the comprehensive initiation research reports comprise of 50-80 pages, including an extensive analysis of the value chain of the IPO candidate, its unique selling proposition, an elaborate analysis of suppliers and clients, a thorough SWOT analysis, a commercial due diligence (i. e. market and competitive analysis), an integrated financial forecast model and a profound company valuation (both DCF methodology and peer group multiples). Before publication, each of Sphene Capital’s research report will be double-checked by a fellow research colleague (“Four-eyes-principle”), ensuring highest quality and avoiding careless mistakes.

After initiation of research coverage, Sphene Capital publishes regular updates of 12-30 pages following relevant news flow from the issuer or major peers, f. ex. after acquisitions or after publication of quarterly results.

Due to Sphene Capital’s extensive experience in equity and bond research, the team has established longstanding contacts to all relevant market players, i. e. institutional investors, family offices and high net-worth individuals as well as journalists. To each of these groups, Sphene Capital’s research analysts have regular contacts during analyst and management roadshows or via daily phone calls. Finally, analysts publish articles in selected stock markets magazines and websites in which the analysts help issuers to improve their popularity on the German capital markets.

Peter Thilo Hasler

Other Reports from Sphene Capital GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch